<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "https://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html lang="en-GB" xml:lang="en-GB" xmlns="https://www.w3.org/1999/xhtml">

<head>
  <title>Psoriatic arthritis</title>
  <meta content="text/html; charset=utf-8" http-equiv="Content-Type" />
  <meta content="" name="description" />
  <meta content="" name="keywords" />

  <meta content="" name="DC.title" />
  <meta content="" name="DC.subject" />
  <meta content="" name="DC.description" />
  <meta content="" name="DC.creator" />
  <meta content="2014-05-21T15:57:54.016999663" name="DC.date" />
  <meta content="" name="DC.language" />
  <style media="all" type="text/css">
    body {
      font-family: 'Liberation Serif', serif;
      font-size: 16.0px
    }

    span.Internetlink {
      color: #0000ff;
      text-decoration: underline
    }

    span.StrongEmphasis {
      font-weight: bold
    }

    a:link {
      color: #0000ff;
      text-decoration: underline
    }

    p.Textbodyindent {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      font-family: Times, serif;
      font-size: 16.0px;
      color: #000000
    }

    p.Standard {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      font-family: 'Times New Roman', serif;
      font-size: 16.0px;
      color: #000000
    }

    p.NormalWeb {
      margin-left: 0;
      margin-right: 0;
      margin-top: 18.670866px;
      margin-bottom: 18.670866px;
      border: none;
      padding: 0;
      font-family: 'Times New Roman', serif;
      font-size: 16.0px;
      color: #000000
    }

    p.Subtitle {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      font-family: 'Times New Roman', serif;
      font-weight: bold;
      font-size: 16.0px;
      color: #000000
    }

    p.Title {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      text-indent: 48.0px;
      text-align: center;
      font-family: 'Times New Roman', serif;
      font-weight: bold;
      font-size: 16.0px;
      color: #000000
    }

    p.BodyTextIndent3 {
      margin-left: 8.390552px;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      text-indent: 0;
      font-family: 'Times New Roman', serif;
      font-size: 16.0px;
      color: #000000
    }

    p.BodyTextIndent2 {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      text-indent: 48.0px;
      font-family: 'Times New Roman', serif;
      font-size: 16.0px;
      color: #000000
    }

    p.Header {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      font-family: 'Times New Roman', serif;
      font-size: 16.0px;
      color: #000000
    }

    h1 {
      margin-left: 0;
      margin-right: 0;
      margin-top: 0;
      margin-bottom: 0;
      border: none;
      padding: 0;
      text-indent: 0;
      text-align: justify;
      font-family: Arial, sans-serif;
      font-weight: bold;
      font-size: 26.666668px;
      color: #000000;
      clear: left
    }

    h5 {
      margin-left: 2.0031495px;
      margin-right: 0;
      margin-top: 15.987401px;
      margin-bottom: 4.006299px;
      border: none;
      padding: 0;
      text-indent: 0;
      text-align: justify;
      font-family: Arial, sans-serif;
      font-style: normal;
      font-weight: normal;
      font-size: 26.666668px;
      color: #000000;
      clear: left
    }

    .listlevel1WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: disc;
      clear: left
    }

    .listlevel2WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: bullet;
      clear: left
    }

    .listlevel3WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: square;
      clear: left
    }

    .listlevel4WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: disc;
      clear: left
    }

    .listlevel5WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: bullet;
      clear: left
    }

    .listlevel6WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: square;
      clear: left
    }

    .listlevel7WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: disc;
      clear: left
    }

    .listlevel8WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: bullet;
      clear: left
    }

    .listlevel9WW8Num2 {
      margin-top: 0;
      margin-bottom: 0;
      list-style-type: square;
      clear: left
    }
  </style>
</head>

<body dir="ltr">
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US">Psoriatic Arthritis</p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US">Topic Highlights</p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US"> </p>
  <ul class="listlevel1WW8Num2">
    <li>
      <p class="Standard" dir="ltr" lang="en-US" xml:lang="en-US">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Psoriatic arthritis (PsA) is an
          inflammatory arthritis occurring in individuals with psoriasis, resulting in functional impairment.</span>
      </p>
    </li>
    <li>
      <p class="Standard" dir="ltr" lang="en-US" xml:lang="en-US">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">This visual presentation focuses
          on types of psoriatic arthritis, the epidemiology, clinical diagnosis, immunopathogenesis, traditional
          systemic therapies, biological agents for PsA and other potential treatments that focus on more aggressive
          treatment to improve the outlook for patients with PsA.</span>
      </p>
    </li>
  </ul>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US">Transcript</p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:center;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US" style="margin-left:0;margin-right:0;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <a href="https://en.wikipedia.org/wiki/Psoriatic_arthritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">Psoriatic arthritis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> (PsA), an aspect
      of </span>
    <a href="https://en.wikipedia.org/wiki/Psoriasis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">psoriasis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">, is a chronic,
    </span>
    <a href="https://en.wikipedia.org/wiki/Autoimmune_disease">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">autoimmune disease</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> characterized by
      inflammation of the skin and joints. Psoriasis affects approximately 2-3% of the general population and the
      prevalence of PsA in psoriasis patients is between 6% </span>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">and 39%. Most
      patients experience a change in signs and symptoms as the disease progresses. The intensity of pain ranges from
      mild to severe. Psoriatic arthritis can occur at any age and affects men and women equally</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. </span>
  </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US">Focus on more aggressive treatment of patients with progressive disease, both with traditional
    disease modifying drugs and emerging biologics has improved the outlook for patients with PsA regarding control of
    symptoms in the joints, enthesium, and skin, inhibition of progressive joint destruction, improvement of function
    and quality of life. It is also possible that the condition remains generally under diagnosed, related to lack of
    awareness by both the patient and physician.</p>
  <p class="Subtitle" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <h5 dir="ltr" id="toc0">Five types of psoriatic arthritis have been defined, that can coexist but tend to occur
    separately in most cases: </h5>
  <p class="NormalWeb" dir="ltr" lang="en-US" style="margin-top:0;margin-bottom:0;text-align:justify" xml:lang="en-US">
    <span class="StrongEmphasis">
      <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">Asymmetric
        arthritis</span>
    </span>
    <span class="StrongEmphasis">
      <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">,</span>
    </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> mildest form of psoriatic arthritis,
      affects any joint such as the knee, hip, ankle or wrist. Inflamed joints are often tender and red. When hands and
      feet are involved, swelling and inflammation in the tendons can cause the fingers and toes to resemble small
      sausages (</span>
    <a href="https://en.wikipedia.org/wiki/Dactylitis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">dactylitis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">).</span>
  </p>
  <p class="NormalWeb" dir="ltr" lang="en-US"
    style="margin-top:0;margin-bottom:0;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="NormalWeb" dir="ltr" lang="en-US" style="margin-top:0;margin-bottom:0;text-align:justify" xml:lang="en-US">
    <a href="https://en.wikipedia.org/wiki/Symmetric_seronegative_polyarthritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">Symmetric arthritis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">,</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> the second most common form of
      psoriatic arthritis,</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> resembles rheumatoid arthritis but
    </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">with a negative rheumatoid
      factor</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. Symptoms often </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">occur in the same joints on both
      sides of the body. Though </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">milder than rheumatoid arthritis, it
      can cause disabling joint damage.</span>
  </p>
  <p class="Standard" dir="ltr" lang="en-US" style="margin-top:18.670866px;margin-bottom:18.670866px;text-align:justify"
    xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Distal interphalangeal predominant
      (DIP)</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, a less common form of psoriatic
      arthritis, affects</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> distal joints of the fingers and
      toes. </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">DIP is sometimes confused with
      osteoarthritis, but psoriatic arthritis usually causes nail changes.</span>
  </p>
  <p class="NormalWeb" dir="ltr" lang="en-US" style="margin-left:0;margin-right:48.0px;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <span class="StrongEmphasis">
      <span
        style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">Spondylitis</span>
    </span>
    <span class="StrongEmphasis">
      <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">,</span>
    </span>
    <span class="StrongEmphasis">
      <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> </span>
    </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">this form of psoriatic arthritis
      causes inflammation with </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">stiffness of the neck, lower back,
    </span>
    <a href="https://en.wikipedia.org/wiki/Sacroiliac">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">sacroiliac</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> or </span>
    <a href="https://en.wikipedia.org/wiki/Spinal_vertebrae">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">spinal vertebrae</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">.</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> With disease progression, movement
      tends to become increasingly painful and difficult.</span>
  </p>
  <p class="NormalWeb" dir="ltr" lang="en-US" style="margin-left:0;margin-right:48.0px;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <a href="https://en.wikipedia.org/wiki/Arthritis_mutilans#Types_of_psoriatic_arthritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">Arthritis mutilans</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, a rare but often debilitating and
      destructive form of psoriatic arthritis, affects the small joints of the hands and feet, sometimes affecting the
      neck and lower back.</span>
  </p>
  <h1 dir="ltr" id="toc1"></h1>
  <p class="BodyTextIndent3" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:48.0px;text-indent:0;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">The CASPAR (ClASsification criteria
      for Psoriatic ARthritis) study group has developed formal classification criteria for categorizing PsA. The
      criteria consisted of established inflammatory articular disease with at least three of the following features –
      current psoriasis, a history of psoriasis, a family history of psoriasis, dactylitis, juxta articular new bone
      formation, rheumatoid factor negativity, and </span>
    <a href="https://en.wikipedia.org/wiki/Nail_dystrophy">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">nail dystrophy</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. </span>
  </p>
  <p class="BodyTextIndent3" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:48.0px;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Evidence now exists documenting the
      central role of </span>
    <a href="https://en.wikipedia.org/wiki/Tumor_necrosis_factor_alpha">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">tumor necrosis factor alpha</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (TNFa) in both PsA and psoriasis.
      High levels of TNF-a are found in psoriatic skin lesions and in the synovial fluid, serum, and synovial tissue of
      patients with PsA. In joints, TNF-a mediates biological processes that can result in cartilage and bone damage,
      including: expression of cartilage destroying </span>
    <a href="https://en.wikipedia.org/wiki/Metalloproteinases">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">metalloproteinases</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> by </span>
    <a href="https://en.wikipedia.org/wiki/Fibroblasts">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">fibroblasts</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and </span>
    <a href="https://en.wikipedia.org/wiki/Chondrocytes">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">chondrocytes</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, maturation and activation of bone
      eroding </span>
    <a href="https://en.wikipedia.org/wiki/Osteoclasts">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">osteoclasts</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> from </span>
    <a href="https://en.wikipedia.org/wiki/Monocytic">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">monocytic</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> stem cells, and </span>
    <a href="https://en.wikipedia.org/wiki/Angiogenesis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">angiogenesis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. In both the joints and the skin,
      TNFa induces the expression of </span>
    <a href="https://en.wikipedia.org/wiki/Endothelial">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">endothelial</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, </span>
    <a href="https://en.wikipedia.org/wiki/Keratinocyte">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">keratinocyte</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and </span>
    <a href="https://en.wikipedia.org/wiki/Dendritic">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">dendritic</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> cell surface adhesion molecules,
      which attract </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">immune cells to sites of
      inflammation. In addition to stimulating pro-inflammatory cells and </span>
    <a href="https://en.wikipedia.org/wiki/Cytokines">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">cytokines</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> in the skin, a key role played by
      TNFα is promotion of </span>
    <a href="https://en.wikipedia.org/wiki/Keratinocyte">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">keratinocyte</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> hyperproliferation and survival,
      which is important in the psoriatic lesion.</span>
  </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:48.0px;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US" style="margin-left:0;margin-right:0;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">Other key
      cytokines, which are increased, and thus potential targets for therapy, include IL-1, IL-6, IL-12, IL-15, and
      IL-18. </span>
    <a href="https://en.wikipedia.org/wiki/T_cell">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">T cell</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> activity is
      significantly upregulated, thus inhibition of T cell activation via blockade of second signal pathways is also a
      promising therapeutic approach, as may be inhibition of intracellular signaling pathways.</span>
  </p>
  <p class="Subtitle" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Synovial biopsy studies have
      documented the similarity of immunohistology of various </span>
    <a href="https://en.wikipedia.org/wiki/Spondyloarthritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">spondyloarthritis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (SpA) subsets, including PsA and
    </span>
    <a href="https://en.wikipedia.org/wiki/Ankylosing_spondylitis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">ankylosing spondylitis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (AS), and distinction of these from
      rheumatoid arthritis (RA). Some distinguishing features of the spondyloarthritides include decreased quantity of
      cellular infiltrate yet more vascularity than seen in RA, infiltration with polymorphonuclear cells and </span>
    <a href="https://en.wikipedia.org/wiki/CD163">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">CD163+</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> macrophages, and upregulation of
      toll-like </span>
    <a href="https://en.wikipedia.org/wiki/Receptor_2">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">receptors 2</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and 4. Angiogenesis is prominent in
      both the </span>
    <a href="https://en.wikipedia.org/wiki/Synovium">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">synovium</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and psoriatic skin lesions, induced
      by </span>
    <a href="https://en.wikipedia.org/wiki/Angiogenic">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">angiogenic</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> growth factors such as </span>
    <a href="https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">vascular endothelial growth factor</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (VEGF), </span>
    <a href="https://en.wikipedia.org/wiki/Transforming_growth_factor_β">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">transforming growth factor β</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (TGFβ), and </span>
    <a href="https://en.wikipedia.org/wiki/Angiopoietins">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">angiopoietins</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. There is an increased interest in
      the bone </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">and enthesial pathology of PsA.
      Recent histologic and MRI studies demonstrate inflammatory infiltrate in the subendosteal region of the bone
      adjacent to the cartilage, often corresponding to bone edema on MRI, and at enthesial insertion sites, not
      typically seen in RA.</span>
  </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:48.0px;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000" xml:lang="en-US">The
    exact cause of PsA is not known. A combination of abnormal immune response, genetic and environmental factors are
    said to play a role in disease development. Other factors that can trigger psoriatic arthritis include skin injury,
    stress, severe sunburn, alcohol, poor nutrition, certain medications and infections, especially streptococcal
    infection. HIV/AIDS leads to flaring of psoriatic arthritis.</p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000" xml:lang="en-US"> </p>
  <p class="NormalWeb" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:9.6px;margin-top:0;margin-bottom:0;background-color:#ffffff;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Some of the symptoms of psoriatic
      arthritis include: </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">scaly skin patches on some areas of
      the body</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, joint pain and tenderness, swelling
      of fingers or toes, morning stiffness and fatigue, </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">eye inflammations like </span>
    <a href="https://en.wikipedia.org/wiki/Conjunctivitis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">conjunctivitis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> or </span>
    <a href="https://en.wikipedia.org/wiki/Iritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">iritis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, nail abnormalities such as </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">discoloration, pitting or lifting of
      the nails. </span>
    <a href="https://en.wikipedia.org/wiki/Pleuritis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">Pleuritis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and </span>
    <a href="https://en.wikipedia.org/wiki/Aortitis">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">aortitis</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> are the other symptoms that could be
      observed in patients with PsA.</span>
  </p>
  <p class="NormalWeb" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:9.6px;margin-top:0;margin-bottom:0;background-color:#ffffff;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US">The skin lesions of psoriasis typically appear before arthritis manifestations, often by as long as
    10 years. Questioning the psoriasis patient about sustained pain and possible swelling in joints or whole digits
    (dactylitis); the presence of prolonged morning stiffness; persistent pain at tendon and ligament insertion sites
    (enthesitis); back and/or buttock pain (spine and sacroiliac inflammation); and fatigue, can help establish the
    diagnosis, and distinguish the condition from osteoarthritis and injury-induced tendonitis. </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US" style="margin-left:0;margin-right:0;text-indent:0;text-align:justify"
    xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">Laboratory tests
      are often unhelpful. </span>
    <a href="https://en.wikipedia.org/wiki/Acute_phase_reactants">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">Acute phase reactants</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> such as </span>
    <a href="https://en.wikipedia.org/wiki/Sed_rate">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">sed rate</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> or CRP may be
      normal and </span>
    <a href="https://en.wikipedia.org/wiki/Rheumatoid_factor">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">rheumatoid factor</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> is usually
      negative. </span>
  </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:0;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">As the disease
      advances, distinctive radiographic features begin to appear that can help differentiate the condition from other
      forms of arthritis. </span>
    <a href="https://en.wikipedia.org/wiki/MRI">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">MRI</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> and </span>
    <a href="https://en.wikipedia.org/wiki/Ultrasound">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">ultrasound</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> may be even more
      sensitive imaging studies, which can detect inflammation at an early stage. </span>
  </p>
  <p class="Header" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000" xml:lang="en-US"> </p>
  <p class="Header" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">A challenge of PsA therapy is
      addressing the multiple clinical domains involved in the disease: arthritis, enthesitis, dactylitis, spine
      disease, skin, and the significant impairment in function and the patient’s quality of life. In patients with
      milder disease, </span>
    <a href="https://en.wikipedia.org/wiki/Non-steroidal_anti-inflammatory_drugs">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">non-steroidal anti-inflammatory drugs</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> (NSAIDs) may be adequate for
      arthritis, while topical ointments like steroid or Vitamin D, or forms of light therapy may be adequate for skin
      disease. However, moderate to severe manifestations in these domains often requires systemic </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">therapy. Drugs such as </span>
    <a href="https://en.wikipedia.org/wiki/Sulfasalazine">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">sulfasalazine</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> or </span>
    <a href="https://en.wikipedia.org/wiki/Methotrexate">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">methotrexate</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> may substantially help arthritis,
      but not always the disease of skin, nails, and entheses. Agents such as cyclosporine may help the skin but not
      adequately the joints, and none of these traditional disease-modifying therapies may help the spine. Thus,
      advances in targeted therapy with the newer biologic agents, especially the TNF antagonists, appear to address all
      domains with significant effectiveness.</span>
  </p>
  <p class="Header" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000" xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US">Non-medication approaches to PsA therapy are a fundamental backdrop to medication therapy. These
    include patient and family education, regular exercise, physical and occupational therapy.</p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:0;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">Biologic
      medications are proteins, which mimic natural biological processes and target specific pro-inflammatory molecules
      and/or cellular receptors. As complex proteins, they must be administered parenterally either subcutaneously,
      intramuscularly, or intravenously. Biologic agents currently approved for treatment of PsA include the anti-tumor
      necrosis factor alpha (TNF-a) compounds, example: </span>
    <a href="https://en.wikipedia.org/wiki/Etanercept">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">etanercept</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">, which mimics the
      natural TNF receptor, and </span>
    <a href="https://en.wikipedia.org/wiki/Infliximab">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">infliximab</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"> and </span>
    <a href="https://en.wikipedia.org/wiki/Adalimumab">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-weight:bold;font-size:26.666668px">adalimumab</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000">, both monoclonal
      antibodies, the former chimeric (combination of mouse and human) and the latter humanized.</span>
  </p>
  <p class="Subtitle" dir="ltr" lang="en-US"
    style="background-color:#ffffff;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="BodyTextIndent2" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">The </span>
    <a href="https://en.wikipedia.org/wiki/TNF_inhibitor">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">anti-TNFα medications</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> have shown the greatest efficacy of
      any treatment to date in the various clinical aspects of PsA. Highly significant improvements in composite
      assessments of joint disease, pain and function were demonstrated in clinical trials with each of the agents.
      Trials with anti-TNF agents, which measured dactylitis and enthesitis response, showed significant benefit.
      Fatigue significantly improved. Serial radiographs of hands and feet showed inhibition of progressive joint
      damage. Skin disease significantly improved with all treatments, although typically substantial clearing of the
      skin lesions took longer than joint improvement. </span>
  </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:48.0px;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="background-color:#ffffff;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US">Significant efficacy of anti-TNF treatment of inflammatory spine symptoms and signs has been
    demonstrated in a closely related disease, ankylosing spondylitis, with some adverse effects. The most significant
    is a slight increase in serious bacterial or opportunistic infections. Administration reactions, either infusion
    reactions with the intravenous drug infliximab, or injections site reactions with the subcutaneously administered
    medicines may occur. Administration reactions are most often mild and self-limited. Other rare reactions, including
    drug-induced autoimmune conditions, which will resolve with discontinuation of the medicine, may also occur. Thus,
    appropriate patient education about and monitoring for such adverse events should be done.</p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:48.0px;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Controlled phase 2 trials have been
      completed with the co-stimulatory blockade agents </span>
    <a href="https://en.wikipedia.org/wiki/Alefacept">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">alefacept</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">. Pilot trials with other biologics
      in development have been completed or are underway, involving agents that are either approved or in development
      for RA and psoriasis.</span>
  </p>
  <p class="BodyTextIndent2" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000" xml:lang="en-US"> </p>
  <p class="BodyTextIndent2" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:0;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Alefacept is a fully human fusion
      protein that blocks interaction between lymphocyte function-associated antigen 3 (</span>
    <a href="https://en.wikipedia.org/wiki/CD58">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">LFA-3</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">) on the antigen-presenting cell and
    </span>
    <a href="https://en.wikipedia.org/wiki/CD2">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">CD2</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> on the T cell, or attracts natural
      killer lymphocytes to interact with CD2 to yield apoptosis of particular T cell clones. It is FDA approved for
      treatment of psoriasis and </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">is administered weekly as a 15 mg
      intramuscular injection, in an alternating 12 weeks on, 12 weeks off regimen in order to allow return of depleted
    </span>
    <a href="https://en.wikipedia.org/wiki/CD4">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">CD4</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> cells in the off period. Modest
      efficacy for arthritis was noted in a controlled trial.</span>
  </p>
  <p class="Textbodyindent" dir="ltr" lang="en-US"
    style="text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US"> </p>
  <p class="Textbodyindent" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <a href="https://en.wikipedia.org/wiki/Abatacept">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">Abatacept</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, a cytotoxic T lymphocyte antigen 4
      immunoglobulin (CTLA4-Ig), is a recombinant human fusion protein that binds to the </span>
    <a href="https://en.wikipedia.org/wiki/CD80">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">CD80</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">/</span>
    <a href="https://en.wikipedia.org/wiki/CD86">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">86</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> receptor on an antigen presenting
      cell, thus blocking the second signal activation of the </span>
    <a href="https://en.wikipedia.org/wiki/CD28">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">CD28</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> receptor on the T-cell. It is
      administered intravenously once per month and has been approved for use in RA and not for PsA. </span>
  </p>
  <p class="Textbodyindent" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;text-indent:48.0px;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Some of the other biological agents
      considered for PsA therapy include Inhibitors of </span>
    <a href="https://en.wikipedia.org/wiki/Interleukin_12">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">IL-12</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">/</span>
    <a href="https://en.wikipedia.org/wiki/Interleukin_23">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">23</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, anti-</span>
    <a href="https://en.wikipedia.org/wiki/Interleukin_15">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">IL-15</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">, monoclonal antibodies directed
      towards inhibition of the </span>
    <a href="https://en.wikipedia.org/wiki/Interleukin-6">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">IL-6</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> receptor (MRA). Modulators of
      intracellular signaling pathways, like </span>
    <a href="https://en.wikipedia.org/wiki/Janus_kinase_3">
      <span class="Internetlink">
        <span style="font-family:Arial,sans-serif;font-size:26.666668px">JAK-3</span>
      </span>
    </a>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> inhibitors, which interrupt
      intracellular signaling induced by multiple pro-inflammatory cytokines in psoriasis and RA, are also potential
      targets for therapy in both joints and skin. </span>
  </p>
  <p class="Title" dir="ltr" lang="en-US"
    style="margin-left:0;margin-right:0;background-color:#ffffff;text-indent:0;text-align:justify;font-family:Arial,sans-serif;font-weight:normal;font-size:26.666668px;color:#000000;text-decoration:underline"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="background-color:#ffffff;text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Healthy diet, healthy weight, regular
    </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">exercise, </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">use of cold and hot packs to minimize
      pain and swelling, </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">relaxation techniques, maintaining
      correct posture to avoid further damage to the affected joints, and moderate exposure to sunlight alleviate
      symptoms of </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">psoriasis.</span>
  </p>
  <p class="Standard" dir="ltr" lang="en-US"
    style="background-color:#ffffff;text-align:justify;font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"
    xml:lang="en-US"> </p>
  <p class="Standard" dir="ltr" lang="en-US" style="text-align:justify" xml:lang="en-US">
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Numerous studies have increased our
      understanding of the basic pathophysiology of PsA, providing support for the clinical effects of targeted therapy.
    </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">The consequent emerging treatments
      for </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">PsA have demonstrated a significant
      benefit for clinical signs and symptoms in the joints, enthesium, skin, and inhibition of joint damage. </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">Observation of the effectiveness of
      new therapeutic agents has helped elucidate the pathogenesis of </span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000">PsA</span>
    <span style="font-family:Arial,sans-serif;font-size:26.666668px;color:#000000"> and psoriasis, which, in turn, may
      lead to more novel and effective interventions.</span>
  </p>
  <center>
    <div id="google_translate_element"></div>
  </center>
  <script type="text/javascript">
    function googleTranslateElementInit() {
      new google.translate.TranslateElement({ pageLanguage: 'en' }, 'google_translate_element');
    }
  </script>

  <script type="text/javascript"
    src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script>

<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>